The Drug-Induced Respiratory Disease Website and App
Frequency - Incidence
Incidence of respiratory adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases
Evidence level/grade
Evidence level for respiratory adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic
Opportunistic pulmonary/systemic infections
Specific risk appears to be low, except in those patients who are being treated with corticosteroids or infliximab for the purpose of an ICI-induced immune-related adverse event (irAE)
Publications
Opportunistic Infections and Immune-Related Adverse Events Associated with Administering Immune Checkpoint Inhibitors: A Narrative Review.
Pharmaceuticals (Basel, Switzerland) 2023 Aug 09;16; — 2023 Aug 09
Immunosuppression for Immune Checkpoint-related Toxicity Can Cause Pneumocystis Jirovecii Pneumonia (PJP) in Non-small-cell Lung Cancer (NSCLC): A Report of 2 Cases.
Clinical lung cancer 2019 May;20;e247-e250 — 2019 May — e247-e250
The Spectrum of Serious Infections Among Patients Receiving Immune Checkpoint Blockade for the Treatment of Melanoma.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2016 Dec 01;63;1490-1493 — 2016 Dec 01 — 1490-1493